- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
PureTech Health to Present at the Jefferies 2016 Healthcare Conference
PureTech Health, across-disciplinary biotech company developing 21st century medicines, today announced that Daphne Zohar, PureTech Health’s Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference.
PureTech Health plc (“PureTech” or the “Company”, LSE: PRTC), a cross-disciplinary biotech company developing 21st century medicines, today announced that Daphne Zohar, PureTech Health’s Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, at 4:00pm GMT.
A webcast of the presentation will be available at https://puretechhealth.com/investors.php
under the Reports and Presentations tab.
About PureTech Health
PureTech
Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biotech
company creating 21st century medicines that modulate the
adaptive human systems. Our therapies target the immune, nervous, and
gastro-intestinal systems by addressing the underlying pathophysiology
of disease from a systems perspective rather than through a single
receptor or pathway. We are advancing more than 20 clinical studies
across our pipeline, with five human proof-of-concept studies and
multiple pivotal or registration studies expected to read out in the
next two years. PureTech Health’s rich and growing research and
development pipeline has been developed in collaboration with some of
the world’s leading scientific experts, who along with PureTech’s
experienced team and board analyze more than 650 scientific discoveries
per year to identify and advance the opportunities we believe hold the
most promise for patients. This process places PureTech Health on the
cutting edge of ground-breaking science and technological innovation and
leads the Company between and beyond existing disciplines. For more
information, visit www.puretechhealth.com
or connect with us on Twitter.
Forward Looking Statement
This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company’s future prospects, developments
and strategies. The forward- looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations, including,
but not limited to, those risks and uncertainties described in the risk
factors included in the company’s regulatory filings. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Listing Rules and the
Disclosure and Transparency Rules, neither the company nor any other
party intends to update or revise these forward- looking statements,
whether as a result of new information, future events or otherwise.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.